Volume 15 Issue 1
Jan.  2024
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2024  >  15(1): 19-25
Wang Haojun, Sun Zejia, Wang Wei. Optimal diagnosis and treatment for renal allograft fibrosis[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 19-25. doi: 10.3969/j.issn.1674-7445.2023156
Citation: Wang Haojun, Sun Zejia, Wang Wei. Optimal diagnosis and treatment for renal allograft fibrosis[J]. ORGAN TRANSPLANTATION, 2024, 15(1): 19-25. doi: 10.3969/j.issn.1674-7445.2023156
shu

Optimal diagnosis and treatment for renal allograft fibrosis

doi: 10.3969/j.issn.1674-7445.2023156

  • Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

More Information
  • Corresponding author: Wang Wei, Email: weiwang0920@163.com
  • Received Date: 2023-08-15
  • Accepted Date: 2023-11-06
    • Available Online: 2023-11-30
  • Publish Date: 2024-01-11
    Abstract
  • Renal allograft fibrosis is one of the common and severe complications after kidney transplantation, which seriously affects the function and survival rate of renal allograft, and may even lead to organ failure and patient death. At present, the researches on renal allograft fibrosis are highly complicated, including immunity, ischemia-reperfusion injury, infection and drug toxicity, etc. The diagnosis and treatment of renal allograft fibrosis remain extremely challenging. In this article, the latest research progress was reviewed and the causes, novel diagnosis and treatment strategies for renal allograft fibrosis were investigated. By improving diagnostic accuracy and optimizing treatment regimen, it is expected to enhance clinical prognosis of kidney transplant recipients, aiming to provide reference for clinicians to deliver proper management for kidney transplant recipients.

     

    • FullText(HTML)
  • loading
    • References(55)
  • [1]
    MCDANIELS JM, SHETTY AC, KUSCU C, et al. Single nuclei transcriptomics delineates complex immune and kidney cell interactions contributing to kidney allograft fibrosis[J]. Kidney Int, 2023, 103(6): 1077-1092. DOI: 10.1016/j.kint.2023.02.018.
    [2]
    FENIG Y, SURESH S, ROCHON C. Long-term survival after kidney transplantation[J]. N Engl J Med, 2022, 386(5): 499. DOI: 10.1056/NEJMc2115207.
    [3]
    WOLFE RA, ROYS EC, MERION RM. Trends in organ donation and transplantation in the United States, 1999-2008[J]. Am J Transplant, 2010, 10(4 Pt 2): 961-972. DOI: 10.1111/j.1600-6143.2010.03021.x.
    [4]
    任滌非, 王於尘, 苗芸. 巨噬细胞在移植肾纤维化中的作用研究进展[J]. 器官移植, 2023, 14(5): 723-729. DOI: 10.3969/j.issn.1674-7445.2023084.

    REN DF, WANG YC, MIAO Y. Research progress on the role of macrophages in renal allograft fibrosis[J]. Organ Transplant, 2023, 14(5): 723-729. DOI: 10.3969/j.issn.1674-7445.2023084.
    [5]
    NANKIVELL BJ, BORROWS RJ, FUNG CL, et al. The natural history of chronic allograft nephropathy[J]. N Engl J Med, 2003, 349(24): 2326-2333. DOI: 10.1056/NEJMoa020009.
    [6]
    SARITAS T, KRAMANN R. Kidney allograft fibrosis: diagnostic and therapeutic strategies[J]. Transplantation, 2021, 105(10): e114-e130. DOI: 10.1097/TP.0000000000003678.
    [7]
    HEILMAN RL, SMITH ML, KURIAN SM, et al. Transplanting kidneys from deceased donors with severe acute kidney injury[J]. Am J Transplant, 2015, 15(8): 2143-2151. DOI: 10.1111/ajt.13260.
    [8]
    STEGALL MD, PARK WD, LARSON TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation[J]. Am J Transplant, 2011, 11(4): 698-707. DOI: 10.1111/j.1600-6143.2010.03312.x.
    [9]
    SERÓN D, MORESO F, RAMÓN JM, et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy[J]. Transplantation, 2000, 69(9): 1849-1855. DOI: 10.1097/00007890-200005150-00019.
    [10]
    MANNON RB, MATAS AJ, GRANDE J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure[J]. Am J Transplant, 2010, 10(9): 2066-2073. DOI: 10.1111/j.1600-6143.2010.03240.x.
    [11]
    SHIMIZU T, TOMA H, HAYAKAWA N, et al. Clinical and pathological analyses of interstitial fibrosis and tubular atrophy cases after kidney transplantation[J]. Nephrology (Carlton), 2016, 21(Suppl 1): 26-30. DOI: 10.1111/nep.12766.
    [12]
    MENON MC, CHUANG PY, LI Z, et al. Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis[J]. J Clin Invest, 2015, 125(1): 208-221. DOI: 10.1172/JCI76902.
    [13]
    MOORE J, MCKNIGHT AJ, SIMMONDS MJ, et al. Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure[J]. JAMA, 2010, 303(13): 1282-1287. DOI: 10.1001/jama.2010.356.
    [14]
    LIU X, LIU K, GUI Z, et al. Single nucleotide polymorphisms of IL-33 gene correlated with renal allograft fibrosis in kidney transplant recipients[J]. J Immunol Res, 2021: 8029180. DOI: 10.1155/2021/8029180.
    [15]
    LIANG H, XU F, WEN XJ, et al. Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion[J]. Eur J Pharmacol, 2017, 812: 18-27. DOI: 10.1016/j.ejphar.2017.06.031.
    [16]
    YUAN PP, LI M, ZHANG Q, et al. 2-phenylacetamide separated from the seed of lepidium apetalum willd. inhibited renal fibrosis via MAPK pathway mediated RAAS and oxidative stress in SHR rats[J]. BMC Complement Med Ther, 2023, 23(1): 207. DOI: 10.1186/s12906-023-04012-w.
    [17]
    EPSTEIN M, KOVESDY CP, CLASE CM, et al. Aldosterone, mineralocorticoid receptor activation, and CKD: a review of evolving treatment paradigms[J]. Am J Kidney Dis, 2022, 80(5): 658-666. DOI: 10.1053/j.ajkd.2022.04.016.
    [18]
    YUAN X, WANG X, LI Y, et al. Aldosterone promotes renal interstitial fibrosis via the AIF-1/Akt/mTOR signaling pathway[J]. Mol Med Rep, 2019, 20(5): 4033-4044. DOI: 10.3892/mmr.2019.10680.
    [19]
    QIANG P, HAO J, YANG F, et al. Esaxerenone inhibits the macrophage-to-myofibroblast transition through mineralocorticoid receptor/TGF-β1 pathway in mice induced with aldosterone[J]. Front Immunol, 2022, 13: 948658. DOI: 10.3389/fimmu.2022.948658.
    [20]
    VALENTIJN FA, KNOPPERT SN, MARQUEZ-EXPOSITO L, et al. Cellular communication network 2 (connective tissue growth factor) aggravates acute DNA damage and subsequent DNA damage response-senescence-fibrosis following kidney ischemia reperfusion injury[J]. Kidney Int, 2022, 102(6): 1305-1319. DOI: 10.1016/j.kint.2022.06.030.
    [21]
    KNOPS N, RAMAZANI Y, DE LOOR H, et al. Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of the CYP3A5 and ABCB1 genes[J]. Nephrol Dial Transplant, 2023, 38(3): 599-609. DOI: 10.1093/ndt/gfac237.
    [22]
    UME AC, WENEGIEME TY, SHELBY JN, et al. Tacrolimus induces fibroblast-to-myofibroblast transition via a TGF-β-dependent mechanism to contribute to renal fibrosis[J]. Am J Physiol Renal Physiol, 2023, 324(5): F433-F445. DOI: 10.1152/ajprenal.00226.2022.
    [23]
    LIU L, GUO J, PANG XL, et al. Exploration of the mechanism of NORAD activation of TGF-β1/Smad3 through miR-136-5p and promotion of tacrolimus-induced renal fibrosis[J]. Ren Fail, 2023, 45(1): 2147083. DOI: 10.1080/0886022X.2022.2147083.
    [24]
    BEN-DOV IZ, MUTHUKUMAR T, MOROZOV P, et al. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis[J]. Transplantation, 2012, 94(11): 1086-1094. DOI: 10.1097/TP.0b013e3182751efd.
    [25]
    ISHII Y, SAWADA T, KUBOTA K, et al. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy[J]. Kidney Int, 2005, 67(1): 321-332. DOI: 10.1111/j.1523-1755.2005.00085.x.
    [26]
    LOUZADA RA, CORRE R, AMEZIANE EL HASSANI R, et al. NADPH oxidase DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis[J]. Eur Respir J, 2021, 57(1): 1901949. DOI: 10.1183/13993003.01949-2019.
    [27]
    SHI Y, TAO M, CHEN H, et al. Ubiquitin-specific protease 11 promotes partial epithelial-to-mesenchymal transition by deubiquitinating the epidermal growth factor receptor during kidney fibrosis[J]. Kidney Int, 2023, 103(3): 544-564. DOI: 10.1016/j.kint.2022.11.027.
    [28]
    HEYLEN L, THIENPONT B, BUSSCHAERT P, et al. Age-related changes in DNA methylation affect renal histology and post-transplant fibrosis[J]. Kidney Int, 2019, 96(5): 1195-1204. DOI: 10.1016/j.kint.2019.06.018.
    [29]
    BROOK NR, WHITE SA, WALLER JR, et al. Fibrosis-associated gene expression in renal transplant glomeruli after acute renal allograft rejection[J]. Br J Surg, 2003, 90(8): 1009-1014. DOI: 10.1002/bjs.4133.
    [30]
    PONTICELLI C, CAMPISE MR. The inflammatory state is a risk factor for cardiovascular disease and graft fibrosis in kidney transplantation[J]. Kidney Int, 2021, 100(3): 536-545. DOI: 10.1016/j.kint.2021.04.016.
    [31]
    SAYIN B, CANVER B, GURLEK DEMIRCI B, et al. Renin-angiotensin system blockage and avoiding high doses of calcineurin inhibitors prevent interstitial fibrosis and tubular atrophy in kidney transplant recipients[J]. Exp Clin Transplant, 2017, 15(Suppl 1): 32-36. DOI: 10.6002/ect.mesot2016.O19.
    [32]
    AKBARI A, FERGUSSON D, KOKOLO MB, et al. Spot urine protein measurements in kidney transplantation: a systematic review of diagnostic accuracy[J]. Nephrol Dial Transplant, 2014, 29(4): 919-926. DOI: 10.1093/ndt/gft520.
    [33]
    OLSON JD, TOOZE JA, BOURLAND DJ, et al. Measurement of renal cortical fibrosis by CT scan[J]. Res Diagn Interv Imaging, 2023, 5: 100024. DOI: 10.1016/j.redii.2023.100024.
    [34]
    HUA C, QIU L, ZHOU L, et al. Value of multiparametric magnetic resonance imaging for evaluating chronic kidney disease and renal fibrosis[J]. Eur Radiol, 2023, 33(8): 5211-5221. DOI: 10.1007/s00330-023-09674-1.
    [35]
    MAO W, DING X, DING Y, et al. Evaluation of interstitial fibrosis in chronic kidney disease by multiparametric functional MRI and histopathologic analysis[J]. Eur Radiol, 2023, 33(6): 4138-4147. DOI: 10.1007/s00330-022-09329-7.
    [36]
    徐小龙, 刘丁, 刘永光, 等. 慢性移植肾纤维化诊断的研究进展[J]. 广东医学, 2014, 35(19): 3094-3096.

    XU XL, LIU D, LIU YG, et al. Research progress in the diagnosis of chronic transplanted kidney fibrosis[J]. Guangdong Med, 2014, 35(19): 3094-3096.
    [37]
    HUANG R, FU P, MA L. Kidney fibrosis: from mechanisms to therapeutic medicines[J]. Signal Transduct Target Ther, 2023, 8(1): 129. DOI: 10.1038/s41392-023-01379-7.
    [38]
    王子杰. 肾移植后肾间质纤维化的诊断及治疗[J]. 肾脏病与透析肾移植杂志, 2014, 23(3): 279-282.

    WANG ZJ. Diagnosis and treatment of renal interstitial fibrosis after kidney transplantation[J]. Chin J Nephrol Dial Transplant, 2014, 23(3): 279-282.
    [39]
    NANKIVELL BJ, BORROWS RJ, FUNG CL, et al. Delta analysis of posttransplantation tubulointerstitial damage[J]. Transplantation, 2004, 78(3): 434-441. DOI: 10.1097/01.tp.0000128613.74683.d9.
    [40]
    CHEN L, LI X, DENG Y, et al. The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII[J]. J Transl Med, 2023, 21(1): 323. DOI: 10.1186/s12967-023-04167-7.
    [41]
    NISHIOKA S, ISHIMURA T, ENDO T, et al. Suppression of allograft fibrosis by regulation of mammalian target of rapamycin-related protein expression in kidney-transplanted recipients treated with everolimus and reduced tacrolimus[J]. Ann Transplant, 2021, 26: e926476. DOI: 10.12659/AOT.926476.
    [42]
    UME AC, WENEGIEME TY, WILLIAMS CR. Calcineurin inhibitors: a double-edged sword[J]. Am J Physiol Renal Physiol, 2021, 320(3): F336-F341. DOI: 10.1152/ajprenal.00262.2020.
    [43]
    SHIGEMATSU T, TAJIMA S, FU R, et al. The mTOR inhibitor everolimus attenuates tacrolimus-induced renal interstitial fibrosis in rats[J]. Life Sci, 2022, 288: 120150. DOI: 10.1016/j.lfs.2021.120150.
    [44]
    BARRERA-CHIMAL J, ESTRELA GR, LECHNER SM, et al. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling[J]. Kidney Int, 2018, 93(6): 1344-1355. DOI: 10.1016/j.kint.2017.12.016.
    [45]
    ZHANG Y, NAKANO D, GUAN Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice[J]. Kidney Int, 2018, 94(3): 524-535. DOI: 10.1016/j.kint.2018.05.002.
    [46]
    王珍, 曹博宁, 侯金易. 肾纤维化的治疗[J]. 家庭医学, 2022(6): 9-11.

    WANG Z, CAO BN, HOU JY. Treatment of renal fibrosis[J]. Fam Med, 2022(6): 9-11.
    [47]
    SUGIMOTO H, LEBLEU VS, BOSUKONDA D, et al. Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis[J]. Nat Med, 2012, 18(3): 396-404. DOI: 10.1038/nm.2629.
    [48]
    INOTANI S, TANIGUCHI Y, NAKAMURA K, et al. Knockout of Zeb2 ameliorates progression of renal tubulointerstitial fibrosis in a mouse model of renal ischemia-reperfusion injury[J]. Nephrol Dial Transplant, 2022, 37(3): 454-468. DOI: 10.1093/ndt/gfab311.
    [49]
    SHATI AA, ALKABLI J, ALFAIFI MY, et al. Comparison of the ameliorative roles of crab chitosan nanoparticles and mesenchymal stem cells against cisplatin-triggered nephrotoxicity[J]. Int J Biol Macromol, 2023, 242(Pt 4): 124985. DOI: 10.1016/j.ijbiomac.2023.124985.
    [50]
    CIANCI R, SIMEONI M, CIANCI E, et al. Stem cells in kidney ischemia: from inflammation and fibrosis to renal tissue regeneration[J]. Int J Mol Sci, 2023, 24(5): 4631. DOI: 10.3390/ijms24054631.
    [51]
    LI S, WANG Y, WANG Z, et al. Enhanced renoprotective effect of GDNF-modified adipose-derived mesenchymal stem cells on renal interstitial fibrosis[J]. Stem Cell Res Ther, 2021, 12(1): 27. DOI: 10.1186/s13287-020-02049-z.
    [52]
    MATHEW AP, UTHAMAN S, BAE EH, et al. Vimentin targeted nano-gene carrier for treatment of renal diseases[J]. J Korean Med Sci, 2021, 36(49): e333. DOI: 10.3346/jkms.2021.36.e333.
    [53]
    TANG TT, WANG B, LI ZL, et al. Kim-1 targeted extracellular vesicles: a new therapeutic platform for RNAi to treat AKI[J]. J Am Soc Nephrol, 2021, 32(10): 2467-2483. DOI: 10.1681/ASN.2020111561.
    [54]
    XIE ZY, DONG W, ZHANG L, et al. NFAT inhibitor 11R-VIVIT ameliorates mouse renal fibrosis after ischemia-reperfusion-induced acute kidney injury[J]. Acta Pharmacol Sin, 2022, 43(8): 2081-2093. DOI: 10.1038/s41401-021-00833-y.
    [55]
    ZHAO H, LUO X, ZHOU Z, et al. Early treatment with xenon protects against the cold ischemia associated with chronic allograft nephropathy in rats[J]. Kidney Int, 2014, 85(1): 112-123. DOI: 10.1038/ki.2013.334.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (197) PDF downloads(42) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return